Asthma and lower airway diseaseDevelopment and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations
Section snippets
Studies
This retrospective analysis included data from 3 double-blind, randomized, parallel-group clinical studies15, 16, 17 of 6 or 12 months' duration for which several candidate predictors were available. The detailed methodologies of the studies are summarized in Table E1 in this article's Online Repository at www.jacionline.org. The studies investigated the efficacy of BUD/FORM MRT compared with the following fixed-dose comparator therapies: (1) the same maintenance dose of inhaled corticosteroid
Study populations and baseline demographics
Demographic and baseline data were similar between the 2 treatment groups (BUD/FORM MRT, n = 3172; fixed-dose ICS/LABA, n = 4274); mean age was 39.5 years, 59% were female, mean time since asthma diagnosis was 14.6 years, and 79% of patients had never smoked. The mean prebronchodilator FEV1 was 72.0%, and the mean ACQ-5 score at randomization was 1.9 (Table I).
Predictors for uncontrolled asthma after 3 months
The univariate analysis of baseline predictors for the risk of uncontrolled asthma at 3 months showed that 8 of the 16 baseline
Discussion
In this analysis of data pooled from several similarly designed studies, we have identified clinical factors that are associated with not achieving a satisfactory level of current asthma control (defined by GINA as uncontrolled asthma). Similarly, we have identified clinical factors associated with increased risk for severe exacerbations requiring treatment with oral corticosteroids, emergency department treatment/hospitalization, or both. By examining factors associated with increased risk of
References (40)
- et al.
TENOR Study Group. Recent asthma exacerbations: a key predictor of future exacerbations
Respir Med
(2007) - et al.
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Lancet
(2002) - et al.
Predictors of symptoms are different from predictors of severe exacerbations from asthma in children
Chest
(2011) - et al.
Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone
Respir Med
(2007) - et al.
Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study
Lancet
(2006) - et al.
Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma Control Study
J Allergy Clin Immunol
(2007) - et al.
Higher BMI is associated with worse asthma control and quality of life but not asthma severity
Respir Med
(2006) - et al.
Obesity is a determinant of asthma control independent of inflammation and lung mechanics
Chest
(2011) - et al.
A comparison of obese and nonobese people with asthma: exploring an asthma-obesity interaction
Chest
(2010) - et al.
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Lancet
(2012)
Relationship of validated psychometric tools to subsequent medical utilization for asthma
J Allergy Clin Immunol
Reliability and predictive validity of the Asthma Control Test administered by telephone calls using speech recognition technology
J Allergy Clin Immunol
The relationship of asthma impairment determined by psychometric tools to future exacerbations
Chest
Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study
Chest
Risk factors and predictive clinical scores for asthma exacerbations in childhood
Chest
Measurement properties and interpretation of three shortened versions of the asthma control questionnaire
Respir Med
Global strategy for asthma management and prevention: GINA executive summary
Eur Respir J
Update on National Asthma Education and Prevention Program pediatric asthma treatment recommendations
Clin Pediatr
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice
Am J Respir Crit Care Med
Association of asthma control with healthcare utilization: a prospective evaluation
Am J Respir Crit Care Med
Cited by (87)
The Role of Inflammatory Phenotype in Patients With Exacerbation-prone Asthma and Ongoing Therapy
2023, Archivos de Bronconeumologia“As-Needed” Inhaled Corticosteroids for Patients With Asthma
2023, Journal of Allergy and Clinical Immunology: In PracticeIdentifying asthma patients at high risk of exacerbation in a routine visit: A machine learning model
2022, Respiratory MedicineDevelopment and Validation of the Asthma Exacerbation Risk Score Using Claims Data
2022, Academic PediatricsIntimate Partner Violence and Adult Asthma Morbidity: A Population-Based Study
2021, Journal of Allergy and Clinical Immunology: In Practice
The analysis was sponsored by AstraZeneca. E.D.B. has served as a consultant to ALK-Abelló, Almirall, Cephalon, Hoffman La Roche, ICON, and MS Consulting Group; been involved with advisory boards for Almirall, AstraZeneca, Boehringer Ingelheim, Elevation Pharma, Forest, GlaxoSmithKline, Merck, Napp, Novartis, and Nycomed; and received lecture fees from ALK-Abelló, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Pfizer, and Takeda; his institution has received remuneration for participation in clinical trials sponsored by Actelion, Aeras, Almirall, AstraZeneca, Boehringer Ingelheim, Forest, GlaxoSmithKline, Hoffman La Roche, Merck, Novartis, Takeda, and TEVA. S.P. and G.E. were employees of AstraZeneca at the time this analysis was conducted. The analysis was funded by AstraZeneca AB, Mölndal, Sweden.
Disclosure of potential conflict of interest: E. D. Bateman has received consulting fees from AstraZeneca for participation in a working group that performed analyses of databases that led to this paper; has received compensation for board membership from Almirall, AstraZeneca, Boehringer Ingelheim, Elevation Pharma, Forest, GlaxoSmithKline, Merck, Napp, Novartis, and Nycomed; has received consultancy fees from ALK-Abelló, Almirall, Cephalon, ICON, and MS Consulting Group; has received or has grants pending from Actelion, Aeras, Almirall, AstraZeneca, Boehringer Ingelheim, Forest, GlaxoSmithKline, Roche/Genentech, Merck, Novartis, Takeda, TEVA, and Cephalon; and has received payment for delivering lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Pfizer, and Takeda, as well as from Novartis for the development of education presentations. R. Buhl has received compensation for board membership from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, and Roche; has received or has grants pending from Boehringer Ingelheim, Novartis, and Roche; and has received compensation for delivering lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, Grifols, GlaxoSmithKline, Novartis, Roche, and Takeda. P. M. O'Byrne has received compensation for board membership from the Joint Oversight Board for an LABA safety study, and has received consultancy fees from AstraZeneca, GlaxoSmithKline, Merck, Boehringer, and Novartis and has received or has grants pending from AstraZeneca, Amgen, Genentech, Axikin, and Novartis. M. Humbert has received consultancy fees from AstraZeneca, GlaxoSmithKline, TEVA, Novartis, and Roche. H. K. Reddel has received consultancy fees from AstraZeneca for a face-to-face meeting at which this manuscript and other studies were discussed; has received compensation for board membership from AstraZeneca, GlaxoSmithKline, Merck, and Novartis; has received consultancy fees from AstraZeneca, Mundipharma, and Novartis; has received or has grants pending from GlaxoSmithKline and AstraZeneca; and has received payment for delivering lectures from AstraZeneca, GlaxoSmithKline, and Novartis. C. Jenkins has received consultancy fees from AstraZeneca, as well as support for travel and other meeting-related expenses; has received compensation for board membership from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis, and Mundipharma; has also received consultancy fees from GlaxoSmithKline, Boehringer Ingelheim, Novartis, and Mundipharma; has received payment for delivering lectures from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Mundipharma and payment for the development of educational presentations from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Mundipharma; and has also been paid an hourly rate for face-to-face individual consultations and for offering advice on regulatory issues for airways disease medications from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Mundipharma. T. W. Harrison has received compensation for being a member of the NAPP advisory board; his institution has received or has grants pending from AstraZeneca; he has received payment from AstraZeneca, GlaxoSmithKline, and Chiesi for delivering lectures; and he has received compensation for travel and other meeting-related expenses from Boehringer Ingelheim. S. Quirce has received payment for delivering lectures from GlaxoSmithKline, AstraZeneca, Chiesi, Boehringer Ingelheim, and MSD (Merck). S. Peterson is employed by AstraZeneca and has received compensation for employment from Novo Nordisk A/S and StatMind AB. G. Eriksson was previously employed by AstraZeneca, from which he also received stock/stock options, and has received consultancy fees from GErik Medical Consulting AB.